Oncology Why is pharma going gaga for radiopharmaceuticals? The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.
Oncology Are radiopharmaceuticals the next breakthrough in oncology? Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.
Partner Content Partner Content Medicines Discovery Catapult relaunches Wolfson Radiochemist... MDC relaunches Wolfson Radiochemistry facility
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
